The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
A Phase I Trial of Intratumoral Administration of Reovirus in Patients With Histologically Confirmed Recurrent Malignant Gliomas
Open accessAbstract
Reovirus is an oncolytic virus with activity in in vivo models of malignant gliomas (MGs). The primary aims were to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of intratumoral administration of reovirus in patients with recurrent MGs. Response, survival, and time to progression (TTP) were secondary aims. Patients were adults, had Karnofsky Performance score > or = 60, received prior radiotherapy with or without chemotherapy, and had up to the third recurrence of MG. Reovirus was administered intratumorally stereotactically at 1 x 10(7), 1 x 10(8), or 1 x 10(9) tissue culture infectious dose 50 (TCID50) in a volume of 0.9 ml. Twelve patients were treated at three dose levels (3, 6, and 3 patients, respectively). Seven were men, median Karnofsky Performance score was 80, and median age was 53.5 years. There were no grade III or IV adverse events (AEs) definitely or probably related to treatment. Ten patients had tumor progression, one had stabilization, and one was not evaluable for response. Median survival was 21 weeks (range, 6-234), and one is alive 54 months after treatment. Median TTP was 4.3 weeks (range, 2.6-39). An MTD was not reached. The intratumoral administration of the genetically unmodified reovirus was well tolerated using these doses and schedule, in patients with recurrent MG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Self-citationReovirus Therapy of Tumors with Activated Ras Pathway
Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K. (1998) · Science · doi:10.1126/science.282.5392.1332 · Cited by 750
Self-citationRampling, R., Cruickshank, G., Papanastassiou, V, Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., Harland, J., McKie, E., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301184 · Cited by 598
The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus
Strong, J. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3351 · Cited by 552
Recent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D., Forsyth, P. A. J., & Bell, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1750 · Cited by 536
Self-citationChiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Self-citationPhase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme
Freeman, A. I., Zakay-Rones, Z., Gomori, J. M., Linetsky, E., Rasooly, L., Greenbaum, E., Rozenman-Yair, S., Panet, A., Libson, E., Irving, C. S., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.016 · Cited by 407
Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.21.13.2508 · Cited by 395
Harrow, S., Papanastassiou, V, Harland, J., Mabbs, R., Petty, R., Fraser, M., Hadley, D., Patterson, J., Brown, S. M., & Rampling, R. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302289 · Cited by 342
Papanastassiou, V, Rampling, R., Fraser, M., Petty, R., Hadley, D., Nicoll, J., Harland, J., Mabbs, R., & Brown, M. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301664 · Cited by 328
Trask, T. W., Trask, R. P., Aguilar-Cordova, E., Shine, H. D., Wyde, P. R., Goodman, J. C., Hamilton, W. J., Rojas-Martinez, A., Chen, S.-H., Woo, S. L. C., et al. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0030 · Cited by 262
Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives
Hirschfeld, S., Ho, P. T. C., Smith, M., & Pazdur, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.138 · Cited by 229
Reovirus as an Oncolytic Agent Against Experimental Human Malignant Gliomas
Wilcox, M. E., Yang, W., Senger, D. L., Rewcastle, N. B., Morris, D. G., Brasher, P. M. A., Shi, Z. Q., Johnston, R. N., Nishikawa, S., Lee, P. W. K., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.12.903 · Cited by 218
Self-citationMTH-68/H Oncolytic Viral Treatment in Human High-Grade Gliomas
Csatary, L. K., Gosztonyi, G., Szeberenyi, J., Fabian, Z., Liszka, V., Bodey, B., & Csatary, C. M. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000021735.85511.05 · Cited by 200
Oncolytic reovirus against ovarian and colon cancer.
Hirasawa, K., Nishikawa, S. G., Norman, K. L., Alain, T., Kossakowska, A. E., & Lee, P. W. K. (2002) · PubMed · Cited by 196
Systemic reovirus therapy of metastatic cancer in immune-competent mice.
Hirasawa, K., Nishikawa, S. G., Norman, K. L., Coffey, M. C., Thompson, B., Yoon, C., Waisman, D. M., & Lee, P. W. K. (2003) · PubMed · Cited by 173
Self-citationOncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas
Shah, A. C., Benos, D. J., Gillespie, G. Y., & Markert, J. M. (2003) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000003651.97832.6c · Cited by 116
Self-citationSmitt, P. A. E. S., Driesse, M. J., Wolbers, J. G., Kros, M., & Avezaat, C. J. J. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00100-x · Cited by 99
Proteolytic Disassembly Is a Critical Determinant for Reovirus Oncolysis
Alain, T., Kim, T. S. Y., Lun, X., Liacini, A., Schiff, L. A., Senger, D. L., & Forsyth, P. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300207 · Cited by 89
Self-citationEfficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals
Yang, W. Q., Lun, X. Q., Palmer, C. A., Wilcox, M. E., Muzik, H., Shi, Z. Q., Dyck, R. H., Coffey, M. C., Thompson, B., Hamilton, M. G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0940 · Cited by 77
Self-citationYang, W. Q., Senger, D. L., Muzik, H., Shi, Z. Q., Johnson, D., Brasher, P. M. A., Rewcastle, N. B., Hamilton, M. G., Rutka, J., Wolff, J. E. A., et al. (2003) · PubMed · Cited by 74
Self-citationLymphocytes protect against and are not required for reovirus-induced myocarditis
Sherry, B., Li, X. Y., Tyler, K. L., Cullen, J. M., & Virgin, H. W. (1993) · Journal of Virology · doi:10.1128/jvi.67.10.6119-6124.1993 · Cited by 63
Viruses for the treatment of malignant glioma.
Gromeier, M., & Wimmer, E. (2001) · PubMed · Cited by 24
Cited by
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Samson, A., Scott, K. J., Taggart, D., West, E. J., Wilson, E., Nuovo, G. J., Thomson, S., Corns, R., Mathew, R. K., Fuller, M. J., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7577 · Cited by 373
Self-citationGlioblastoma multiforme: State of the art and future therapeutics
Harter, D., Wilson, T., & Karajannis, M. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.132138 · Cited by 327
Mao, H., LeBrun, D. G., Yang, J., Zhu, V. F., & Li, M. (2012) · Cancer Investigation · doi:10.3109/07357907.2011.630050 · Cited by 266
Geletneky, K., Hajda, J., Angelova, A. L., Leuchs, B., Capper, D., Bartsch, A. J., Neumann, J.-O., Schöning, T., Hüsing, J., Beelte, B., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.016 · Cited by 260
Metadata
- Authors
- Forsyth, P., Roldán, G., George, D., Wallace, C., Palmer, C. A., Morris, D., Cairncross, G., Matthews, M. V., Markert, J., Gillespie, Y., Coffey, M., Thompson, B., & Hamilton, M.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 16
- Issue
- 3
- Pages
- 627-632
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W1987741335
- Cited by
- 278
- References
- 24
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.